Primary Category:

Treatment Protocols

Disease Category:

Molecular Profiling


Temporarily Closed

MATCH Treatment Subprotocol K2: Phase 2 Study of Erdafitinib (JNJ-42756493) in Patients with Tumors with FGFR Mutations and Fusions

(See required screening study ECOG-ACRIN EAY131)

Open  to participants with results from one of the designated outside laboratories indicating a “rare variant that is an actionable Mutation of Interest (aMOI) for specific designated rare variant subprotocols. See Appendix XIV of the main protocol for a list of the designated laboratories and applicable subprotocols.

The consent form for this sub-study is available upon request when a patient at your site is assigned to the sub-study.  Please contact Amber Boerner, or 406-969-6067, for the consent & for any questions.

Effective today, July 18th, 2019, Subprotocol K2: Phase 2 is suspended due to the completion of accrual.